Doctors warn of potential risks from prolonged Ozempic (semaglutide) use, citing emerging data on long-term GLP-1 receptor agonist safety, according to Dr. Sheila Armstrong, an endocrinologist at the National Institutes of Health. The surge in adolescent prescriptions has intensified scrutiny of metabolic and gastrointestinal side effects.
Why This Matters: A Growing Clinical Concern
GLP-1 receptor agonists like Ozempic, originally approved for type 2 diabetes, have seen off-label use for weight management. The Journal of the American Medical Association (JAMA) reported a 600% rise in adolescent prescriptions between 2020 and 2023, raising alarms about uncharted long-term consequences. Dr. Armstrong, lead author of a 2026 meta-analysis in The New England Journal of Medicine, notes, “We lack longitudinal data on puberty-related hormonal interactions and gastrointestinal motility changes in this age group.”
In Plain English: The Clinical Takeaway
- GLP-1 agonists mimic a gut hormone to reduce appetite and blood sugar, but long-term effects on adolescent development are unclear.
- Common side effects include nausea, vomiting, and diarrhea; rare but serious risks include pancreatitis and thyroid tumors.
- Patients should discuss risks vs. benefits with a healthcare provider, especially for off-label use.
Deep Dive: Clinical Data and Regional Implications
Phase III trials for Ozempic in obesity (2017-2020) involved 5,000+ participants, showing 15% average weight loss over 68 weeks. However, these studies excluded individuals under 18, per FDA guidelines. A 2025 The Lancet review found 23% of adolescents using GLP-1 agonists reported persistent gastrointestinal distress, compared to 8% in adults.
| Parameter | Ozempic (2020-2023) | Other GLP-1 Agonists |
|---|---|---|
| Adolescent Use Increase | 600% | 120% (liraglutide) |
| Common Side Effects | Nausea (45%), Diarrhea (30%) | Similar, with higher incidence in liraglutide |
| Regulatory Status | Approved for adults; off-label in adolescents | EMA restricts use in those under 18 |
Funding for key trials came from Novo Nordisk, the drug’s manufacturer, though independent analyses by the CDC and WHO have corroborated safety profiles. Dr. Amara Kofi, a public health epidemiologist at the CDC, states, “While short-term efficacy is clear, we need 10+ year follow-ups to assess impacts on bone density, mental health, and metabolic adaptation in growing bodies.”
Contraindications & When to Consult a Doctor
Patients with a history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disorders should avoid GLP-1 agonists. Immediate medical attention is required for symptoms like severe abdominal pain, jaundice, or persistent vomiting. The FDA advises monitoring for thyroid nodules via ultrasound every 6-12 months during treatment.
What’s Next: Regulatory and Research Trends
The FDA is reviewing proposals to expand Ozempic’s label for adolescent use, pending additional data. Meanwhile, the EMA has issued a cautionary statement, citing “insufficient evidence of long-term safety in pediatric populations.” A 2026 JAMA Internal Medicine study found that 34% of adolescents prescribed GLP-1 agonists had comorbid mental health conditions, prompting calls for integrated care models.
